Results for tag: "Gastro Intestinal Adenocarcinoma Drug"

Gastro Intestinal Adenocarcinoma (GIA) is a type of cancer that affects the gastrointestinal tract. It is the most common type of gastrointestinal cancer and is typically treated with a combination of chemotherapy, radiation therapy, and surgery. Oncology drugs are used to treat GIA and can be divided into two categories: targeted therapies and immunotherapies. Targeted therapies are designed to target specific molecules or pathways in cancer cells, while immunotherapies are designed to stimulate the body's own immune system to fight cancer. The Gastro Intestinal Adenocarcinoma Drug market is a rapidly growing segment of the oncology drug market. It is driven by the increasing prevalence of GIA, the development of new treatments, and the increasing demand for personalized treatments. Companies in this market include Roche, Merck, AstraZeneca, Novartis, and Pfizer. Show Less Read more